Brenner, A. J., Floyd, J., Fichtel, L., Michalek, J., Kanakia, K. P., Huang, S., . . . Lee, E. Q. (2021). Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Sci Rep.

Brenner, Andrew J., John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, et Eudocia Quant Lee. "Phase 2 Trial of Hypoxia Activated Evofosfamide (TH302) for Treatment of Recurrent Bevacizumab-refractory Glioblastoma." Sci Rep 2021.

Brenner, Andrew J., et al. "Phase 2 Trial of Hypoxia Activated Evofosfamide (TH302) for Treatment of Recurrent Bevacizumab-refractory Glioblastoma." Sci Rep 2021.